Keros Therapeutics (NASDAQ:KROS) Downgraded by Guggenheim to “Neutral”

Guggenheim lowered shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a neutral rating in a research report sent to investors on Monday morning, MarketBeat.com reports.

A number of other equities research analysts have also recently commented on KROS. Scotiabank reduced their price objective on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research note on Friday. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating for the company. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Wells Fargo & Company raised their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Finally, HC Wainwright reduced their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Stock Up 3.1 %

NASDAQ KROS opened at $19.42 on Monday. The company has a market capitalization of $786.65 million, a price-to-earnings ratio of -3.73 and a beta of 1.20. Keros Therapeutics has a twelve month low of $15.67 and a twelve month high of $73.00. The stock has a fifty day simple moving average of $58.29 and a 200 day simple moving average of $52.50.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.33) EPS. Research analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KROS. KBC Group NV grew its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics during the 2nd quarter worth $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics during the third quarter worth about $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.